Publications

• Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.
  ESMO Open Volume: 10 Page(s): 104538
  04/01/2025 Authors: Chiang AC; Olmedo Garcia ME; Carlisle JW; Dowlati A; Reguart N; Felip E; Jost PJ; Steeghs N; Stec R; Gadgeel SM
• A Response to the Letter to the Editor: "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation ofPhase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC".
  J Thorac Oncol Volume: 20 Page(s): e53
  04/01/2025 Authors: Carlisle JW; Pentz RD; Ramalingam SS
• Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.
  Nat Commun Volume: 16 Page(s): 2324
  03/08/2025 Authors: Shu C; Li J; Rui J; Fan D; Niu Q; Bai R; Cicka D; Doyle S; Wahafu A; Zheng X
• Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.
  Clin Cancer Res Volume: 31 Page(s): 529 - 542
  02/03/2025 Authors: Altan M; Lopes G; Hiltermann TJN; Govindan R; Villaruz LC; Calvo E; Edelman MJ; Furqan M; Neal J; Felip E
• Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
  Cancer Volume: 131 Page(s): e35738
  02/01/2025 Authors: Sands JM; Champiat S; Hummel H-D; Paulson KG; Borghaei H; Alvarez JB; Carbone DP; Carlisle JW; Choudhury NJ; Clarke JM
• Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.
  Future Oncol Volume: 21 Page(s): 63 - 71
  01/01/2025 Authors: Higgins JP; Carlisle JW; Moniri NH; Gupta S; Oduah EI; Leal T
• Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC.
  J Thorac Oncol Volume: 19 Page(s): 1509 - 1511
  11/01/2024 Authors: Carlisle JW; Pentz RD; Ramalingam SS
• Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade.
  J Clin Oncol Volume: 42 Page(s): 2367 - 2371
  07/10/2024 Authors: Carlisle J; Liu Y; Leal T
• Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis.
  J Immunother Cancer Volume: 12
  03/26/2024 Authors: Patel JS; Woo Y; Draper A; Jansen CS; Carlisle JW; Innominato PF; Lvi FA; Dhabaan L; Master VA; Bilen MA
• Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.
  Future Oncol Volume: 20 Page(s): 2503 - 2508
  01/01/2024 Authors: Ramalingam SS; Carlisle JW
• Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
  Nat Med Volume: 30 Page(s): 303
  01/01/2024 Authors: Chaft JE; Oezkan F; Kris MG; Bunn PA; Wistuba II; Kwiatkowski DJ; Owen DH; Tang Y; Johnson BE; Lee JM
• Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
  Oncologist Volume: 28 Page(s): 1055 - 1063
  12/11/2023 Authors: Lalonde CS; Switchenko JM; Behera M; Bilen MA; Owonikoko TK; Kaufman JL; Nooka AK; Lewis CM; Hitron E; Collins H
• Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
  Cancer Volume: 129 Page(s): 3713 - 3723
  12/01/2023 Authors: McCall NS; Janopaul-Naylor JR; McGinnis HS; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal TA
• BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
  NPJ Vaccines Volume: 8 Page(s): 179
  11/21/2023 Authors: Valanparambil RM; Lai L; Johns MA; Davis-Gardner M; Linderman SL; McPherson TO; Chang A; Akhtar A; Gamarra ELB; Matia H
• Advancing immunotherapy in small cell lung cancer.
  Cancer Volume: 129 Page(s): 3525 - 3534
  11/15/2023 Authors: Carlisle JW; Leal T
• Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer.
  Proc Natl Acad Sci U S A Volume: 120 Page(s): e2221985120
  10/10/2023 Authors: Im SJ; Obeng RC; Nasti TH; McManus D; Kamphorst AO; Gunisetty S; Prokhnevska N; Carlisle JW; Yu K; Sica GL
• Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
  J Clin Oncol Volume: 40 Page(s): 3808 - 3816
  11/20/2022 Authors: Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH
• A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
  Clin Lung Cancer Volume: 23 Page(s): e400 - e404
  11/01/2022 Authors: Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S
• Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
  Nat Med Volume: 28 Page(s): 2155 - 2161
  10/01/2022 Authors: Chaft JE; Oezkan F; Kris MG; Bunn PA; Wistuba II; Kwiatkowski DJ; Owen DH; Tang Y; Johnson BE; Lee JM
• Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era.
  Radiother Oncol Volume: 174 Page(s): 133 - 140
  09/01/2022 Authors: McCall NS; McGinnis HS; Janopaul-Naylor JR; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal T
• Phase I Study of Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
  Volume: 17 Page(s): S541 - S541
  09/01/2022 Authors: Mccall NS; Switchenko JM; Tian S; Stokes WA; Kahn S; Kesarwala AH; Shelton JW; Szabo SM; Steuer CE; Carlisle JW
• Impact of Radiation Dose to the Immune Cells in Unresectable or Stage III Non-Small Cell Lung Cancer in the Durvalumab Era
  Volume: 17 Page(s): S109 - S109
  09/01/2022 Authors: Mccall NS; McGinnis HS; Janopaul-Naylor JR; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal T
• Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.
  J Immunother Cancer Volume: 10
  07/01/2022 Authors: Carlisle JW; Jansen CS; Cardenas MA; Sobierajska E; Reyes AM; Greenwald R; Del Balzo L; Prokhnevska N; Kucuk O; Carthon BC
• High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
  JTO Clin Res Rep Volume: 3 Page(s): 100328
  06/01/2022 Authors: Piper-Vallillo AJ; Rotow JK; Aredo JV; Shaverdashvili K; Luo J; Carlisle JW; Husain H; Muzikansky A; Heist RS; Rangachari D
• Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies.
  Am Soc Clin Oncol Educ Book Volume: 41 Page(s): e286 - e293
  06/01/2021 Authors: Carlisle JW; Harvey RD
• Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
  Immunotherapy Volume: 13 Page(s): 727 - 734
  06/01/2021 Authors: Sands JM; Mandrekar SJ; Kozono D; Oxnard GR; Hillman SL; Wigle DA; Govindan R; Carlisle J; Gray J; Salama JK
• An update on the immune landscape in lung and head and neck cancers (vol 70, pg 505, 2020)
  CA-A CANCER JOURNAL FOR CLINICIANS Volume: 71 Page(s): 280 - 280
  03/08/2021 Authors: Carlisle JW; Steuer CE; Owonikoko TK; Saba NF
• YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
  J Thorac Oncol Volume: 16 Page(s): 464 - 476
  03/01/2021 Authors: Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR
• Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
  Cancer Volume: 126 Page(s): 5040 - 5049
  12/01/2020 Authors: Nazha B; Goyal S; Chen Z; Engelhart A; Carlisle JW; Beardslee TJ; Gill H; Odikadze L; Liu Y; Mishra MK
• An update on the immune landscape in lung and head and neck cancers.
  CA Cancer J Clin Volume: 70 Page(s): 505 - 517
  11/01/2020 Authors: Carlisle JW; Steuer CE; Owonikoko TK; Saba NF
• Considerations for cancer immunotherapy biomarker research during COVID-19.
  Endocr Relat Cancer Volume: 27 Page(s): C1 - C8
  09/01/2020 Authors: Carlisle JW; Jansen CS; Bilen MA; Kissick H
• KRAS G12C mutation associated outcomes among patients with locally advanced non-small cell lung cancer.
  Volume: 38
  05/20/2020 Authors: Qian D; Behera M; Steuer CE; Pakkala S; Carlisle JW; Owonikoko TK; Fischer-Valuck BW; Kesarwala AH; Bradley J; Curran WJ
• High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience.
  Volume: 38
  05/20/2020 Authors: Piper-Vallillo A; Rotow JK; Aredo J; Shaverdashvili K; Luo J; Carlisle JW; Husain H; Muzikansky A; Heist RS; Rangachari D
• Integrating Genetic and Genomic Testing Into Oncology Practice.
  Am Soc Clin Oncol Educ Book Volume: 40 Page(s): e259 - e263
  05/01/2020 Authors: Domchek SM; Mardis E; Carlisle JW; Owonikoko TK
• Improving outcomes for brain metastases in EGFR mutated NSCLC.
  Transl Lung Cancer Res Volume: 8 Page(s): S355 - S359
  12/01/2019 Authors: Carlisle JW; Ramalingam SS
• An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
  Nature Volume: 576 Page(s): 465 - 470
  12/01/2019 Authors: Jansen CS; Prokhnevska N; Master VA; Sanda MG; Carlisle JW; Bilen MA; Cardenas M; Wilkinson S; Lake R; Sowalsky AG
• CD8 T-cell infiltration into renal tumors requires a supportive antigen-presenting niche
  Volume: 79
  07/01/2019 Authors: Jansen CS; Prokhnevska N; Master VA; Carlisle JW; Bilen MA; Reyes AM; Kissick HT
• Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.
  Volume: 37
  05/20/2019 Authors: Nazha B; Chen Z; Goyal S; Engelhart A; Carlisle JW; Beardslee T; Gill H; Odikadze L; Liu Y; Mishra MK
• Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.
  Future Oncol Volume: 15 Page(s): 805 - 816
  03/01/2019 Authors: Carlisle JW; Ramalingam SS
• A banner year for immunotherapy and targeted therapy.
  Nat Rev Clin Oncol Volume: 16 Page(s): 79 - 80
  02/01/2019 Authors: Carlisle JW; Ramalingam SS
• Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
  Bone Marrow Transplant Volume: 53 Page(s): 826 - 831
  07/01/2018 Authors: Khoury HJ; Langston AA; Kota VK; Wilkinson JA; Pusic I; Jillella A; Bauer S; Kim AS; Roberts D; Al-Kadhimi Z
• How I treat older patients with acute myeloid leukemia.
  Cancer Volume: 124 Page(s): 2472 - 2483
  06/15/2018 Authors: Arellano M; Carlisle JW
• Immunologic profile and prognostic significance of tumor-infiltrating lymphocytes in renal cell carcinoma.
  Volume: 36
  02/20/2018 Authors: Khan AI; Jansen CS; Carlisle JW; Melnick KR; Kim KS; Hosseinzadeh F; Prokhnevska N; Bilen MA; Master VA; Kissick HT
• The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
  Expert Opin Investig Drugs Volume: 27 Page(s): 163 - 170
  02/01/2018 Authors: Bilen MA; Carlisle JW; Sonpavde G
• Synchronous and metachronous second malignancies in multiple myeloma (MM).
  Volume: 33
  05/20/2015 Authors: Wilkinson JA; Fiala MA; Vij R; Finney J; Stockerl-Goldstein K; Wildes TM
• Individual differences in vulnerability for self-injurious behavior: studies using an animal model.
  Behav Brain Res Volume: 217 Page(s): 148 - 154
  02/02/2011 Authors: Muehlmann AM; Wilkinson JA; Devine DP